Long-Term Efficacy of Guselkumab on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through Two Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naïve Patients With Psoriatic Arthritis

The study investigates the long-term efficacy of Guselkumab (GUS) on fatigue in biologic-naïve patients with Psoriatic Arthritis (PsA) over a 2-year period. It is a Phase 3, randomized, double-blind, placebo-controlled study. The analysis identifies early treatment targets and demonstrates that GUS significantly reduces fatigue in patients with PsA. The findings suggest that GUS is an effective treatment option for managing fatigue associated with PsA, providing sustained benefits over the long term. The study's robust design and duration strengthen the validity of these conclusions.